Crispr Therapeutics Ag Earnings

Crispr Therapeutics Ag’s revenue jumped 71.63% since last year same period to $0.87Mn in the Q1 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -97.53% fall in its revenue since last 3-months.

Crispr Therapeutics Ag’s net profit fell -16.64% since last year same period to $-136Mn in the Q1 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -264.49% fall in its net profits since last 3-months.

Crispr Therapeutics Ag’s net profit margin jumped 32.04% since last year same period to -15722.08% in the Q1 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -14648.27% fall in its net profit margins since last 3-months.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.3 - a 9.09% jump from last quarter’s estimates.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.3.

Crispr Therapeutics Ag’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Crispr Therapeutics Ag has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.